Mutual of America Capital Management LLC Trims Stake in Intuitive Surgical, Inc. $ISRG

Mutual of America Capital Management LLC decreased its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.4% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 38,947 shares of the medical equipment provider’s stock after selling 2,235 shares during the period. Mutual of America Capital Management LLC’s holdings in Intuitive Surgical were worth $17,418,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in ISRG. SteelPeak Wealth LLC boosted its stake in shares of Intuitive Surgical by 28.7% during the 3rd quarter. SteelPeak Wealth LLC now owns 41,993 shares of the medical equipment provider’s stock worth $18,781,000 after purchasing an additional 9,364 shares during the last quarter. Amalgamated Bank boosted its position in Intuitive Surgical by 2.2% during the second quarter. Amalgamated Bank now owns 81,542 shares of the medical equipment provider’s stock worth $44,311,000 after acquiring an additional 1,772 shares during the last quarter. Bessemer Group Inc. grew its stake in Intuitive Surgical by 89.3% in the 2nd quarter. Bessemer Group Inc. now owns 788,328 shares of the medical equipment provider’s stock worth $428,386,000 after acquiring an additional 371,806 shares during the period. Sax Wealth Advisors LLC lifted its stake in shares of Intuitive Surgical by 218.1% during the 2nd quarter. Sax Wealth Advisors LLC now owns 2,456 shares of the medical equipment provider’s stock worth $1,334,000 after purchasing an additional 1,684 shares during the period. Finally, World Investment Advisors boosted its holdings in shares of Intuitive Surgical by 238.3% during the third quarter. World Investment Advisors now owns 5,399 shares of the medical equipment provider’s stock worth $2,415,000 after purchasing an additional 3,803 shares during the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock opened at $523.99 on Monday. Intuitive Surgical, Inc. has a 1-year low of $425.00 and a 1-year high of $609.08. The company has a market capitalization of $187.84 billion, a PE ratio of 66.41, a P/E/G ratio of 4.26 and a beta of 1.67. The business has a 50-day moving average of $562.32 and a 200-day moving average of $511.56.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 EPS for the quarter, topping the consensus estimate of $2.27 by $0.26. Intuitive Surgical had a return on equity of 15.06% and a net margin of 28.38%.The business had revenue of $2.87 billion for the quarter, compared to analysts’ expectations of $2.72 billion. During the same quarter in the previous year, the firm posted $2.21 earnings per share. The company’s revenue was up 18.8% compared to the same quarter last year. On average, equities analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ISRG. Barclays reissued an “overweight” rating and issued a $686.00 price target (up from $635.00) on shares of Intuitive Surgical in a research note on Wednesday, January 7th. Truist Financial raised their price objective on Intuitive Surgical from $620.00 to $650.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Zacks Research lowered Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 21st. The Goldman Sachs Group reissued a “buy” rating and set a $714.00 target price on shares of Intuitive Surgical in a research report on Friday, January 9th. Finally, Argus raised their price target on shares of Intuitive Surgical from $600.00 to $630.00 in a report on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $617.57.

Insider Buying and Selling

In other news, EVP Brian Edward Miller sold 3,500 shares of the stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $575.00, for a total transaction of $2,012,500.00. Following the completion of the transaction, the executive vice president directly owned 5,758 shares in the company, valued at approximately $3,310,850. This represents a 37.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Myriam Curet sold 7,562 shares of Intuitive Surgical stock in a transaction on Tuesday, October 28th. The stock was sold at an average price of $548.43, for a total transaction of $4,147,227.66. Following the completion of the sale, the executive vice president owned 353 shares of the company’s stock, valued at approximately $193,595.79. This trade represents a 95.54% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 55,714 shares of company stock worth $31,617,799 over the last 90 days. 0.70% of the stock is currently owned by corporate insiders.

More Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Q4 results beat Wall Street: Revenue and adjusted EPS topped estimates, backed by higher procedure volumes and system demand — a primary near‑term driver of recurring instrument sales. Reuters: Intuitive Surgical beats quarterly estimates on demand for surgical robots
• Positive Sentiment: Analysts boost some targets and reaffirm conviction: Bernstein raised its target sharply (big upside), Raymond James and BTIG reaffirmed/outperform with higher targets — supporting upside potential from elongation of the company’s growth runway. Benzinga: Analysts revise forecasts after Q4
• Neutral Sentiment: Guidance is measured: Management expects mid‑teens da Vinci procedure growth (midpoint ~14%) and 2026 gross margin around 67–68%, while flagging higher operating expenses for R&D — signaling steady growth but potential margin/operating‑leverage moderation. MarketBeat: Intuitive Surgical Just Proved the Growth Engine Still Runs
• Neutral Sentiment: JURA clinical update and milestone PRs add long‑term optionality: Early imaging data from the JURA feasibility study and a new 20 million‑patient da Vinci milestone reinforce long‑term growth narratives beyond core platforms. TipRanks: JURA feasibility study update GlobeNewswire: 20 Million Patients Benefit from da Vinci Surgery
• Negative Sentiment: Tariffs and gross‑margin pressure noted: Management expects tariffs to cut gross margins (about a 1.2% headwind in 2026) and flagged some gross‑margin decline vs. recent quarters — a medium‑term profitability risk. Zacks: Q4 beat but gross margin declines
• Negative Sentiment: Mixed analyst moves and a few downgrades: Some firms trimmed targets or moved to in‑line/hold (Evercore, Zacks), creating near‑term debate over valuation vs. growth and muting upside for traders focused on short‑term catalysts. The Fly: Evercore lowers price target

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.